Tongzhou Cohort Study

Long-term Impact of Overweight/Obesity and Hypertension on Cardiovascular Risk in Middle-aged and Elderly Adults: A Cohort Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05156580

Enrollment

31080

Registered

2021-12-14

Start date

2016-07-01

Completion date

2026-09-01

Last updated

2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Obesity

Keywords

Obesity, Hypertension, Cardiovascular risk

Brief summary

Long-term Impact of Overweight/Obesity and Hypertension on Cardiovascular Risk in Middle-aged and Elderly Adults

Detailed description

Overweight and obesity are major risk factors associated with the development of hypertension, poor blood pressure control, and adverse cardiovascular outcomes. However, evidence regarding the long-term impact of overweight/obesity and hypertension on cardiovascular risk in middle-aged and elderly populations remains limited. Therefore, the present study aims to evaluate the long-term effects of overweight/obesity and hypertension on cardiovascular risk in middle-aged and elderly adults.Additionally, a subgroup analysis will be conducted in participants with sarcopenia to assess the influence of blood pressure on prognosis, exploring potential interactions between muscle loss, hypertension, and cardiovascular outcomes.

Interventions

OTHERNo intervention

This is an observational study without any intervention

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

45 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Ages of ≥ 45 years * Participants from routine health examinations at Tongzhou Community Health Service Center * Availability for follow-up until 2026 * No major barriers to provide written consent

Exclusion criteria

* NA

Design outcomes

Primary

Measure	Time frame	Description
Percentage of participants with major adverse cardiovascular events (MACEs)	2021-2026	Percentage of participants with major adverse cardiovascular events (MACEs), including all-cause death, nonfatal myocardial infarction (MI), nonfatal stroke and coronary revascularization.

Secondary

Measure	Time frame	Description
Percentage of participants with MI	2021-2026	Percentage of participants with fatal and nonfatal MI.
Percentage of participants with stroke	2021-2026	Percentage of participants with fatal and nonfatal stroke.
Percentage of participants undergoing coronary revascularization	2021-2026	Percentage of participants undergoing ischemia- and non-ischemia-driven coronary revascularization.
Change in BP control rate	2021-2026	Change in BP control rate (office BP: SBP \< 140 mmHg and DBP \< 90 mmHg) from baseline to follow-up.
Percentage of participants with all-cause death	2021-2026	Percentage of participants with cardiovascular, non-cardiovascular and undetermined death.
Change in estimated glomerular filtration rate (eGFR)	2021-2026	Change in estimated glomerular filtration rate (eGFR) in ml/min/1.73m2 from baseline to follow-up.
Change in low-density lipoprotein-cholesterol (LDL-c)	2021-2026	Change in low-density lipoprotein-cholesterol (LDL-c) in mmol/L from baseline to follow-up.
Percentage of participants with Metabolic dysfunction-associated steatotic liver disease (MASLD)	2021-2026	Percentage of participants with Metabolic dysfunction-associated steatotic liver disease.
Change in SBP	2021-2026	Change in SBP from baseline to follow-up.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026